Aug. 12 at 4:51 PM
$ASRT The worst of it is over imo. By Q3 they will be able to show Rolvedon and Sympazan can grow going forward. Hopefully they just settle out (or get dismissed) several more of the shareholder lawsuits they inherited from Spectrum. Getting those off the 10Q would be nice. Cash will grow and be over
$100M. Brandon made it clear he isn't going to piss it away on something just to pump up the stock,it's the right fit for the right price or they just wait. Conservative but also smart for the long-haul. Otrexup is out. Hopefully they can find a way to get a few $ for it and, while they are at it, clear off some of the other misc products even if it hits top line revenue number. They need to be lean (cut more expenses), clean (get rid of historical issues), and focused (get themselves down to growing two product lines). That would be the end of "transition" phase. They can then 1. close on a product line with $ or 2. if they can't find anything to buy then sell themselves. Cheap at
$0.83.
